166 related articles for article (PubMed ID: 266705)
1. Synthetic peptides with the biological activities and specificity of human C3a anaphylatoxin.
Hugli TE; Erickson BW
Proc Natl Acad Sci U S A; 1977 May; 74(5):1826-30. PubMed ID: 266705
[TBL] [Abstract][Full Text] [Related]
2. The active site of human C4a anaphylatoxin.
Hugli TE; Kawahara MS; Unson CG; Molinar-Rode R; Erickson BW
Mol Immunol; 1983 Jun; 20(6):637-45. PubMed ID: 6603573
[TBL] [Abstract][Full Text] [Related]
3. The active site of C3a anaphylatoxin.
Caporale LH; Tippett PS; Erickson BW; Hugli TE
J Biol Chem; 1980 Nov; 255(22):10758-63. PubMed ID: 6968751
[TBL] [Abstract][Full Text] [Related]
4. Purification and partial characterization of human and porcine C3a anaphylatoxin.
Hugli TE; Vallota EH; Müller-Eberhard HJ
J Biol Chem; 1975 Feb; 250(4):1472-8. PubMed ID: 803505
[TBL] [Abstract][Full Text] [Related]
5. Active site of C3a anaphylatoxin: contributions of the lipophilic and orienting residues.
Unson CG; Erickson BW; Hugli TE
Biochemistry; 1984 Feb; 23(4):585-9. PubMed ID: 6608957
[TBL] [Abstract][Full Text] [Related]
6. C4a: the third anaphylatoxin of the human complement system.
Gorski JP; Hugli TE; Müller-Eberhard HJ
Proc Natl Acad Sci U S A; 1979 Oct; 76(10):5299-302. PubMed ID: 291947
[TBL] [Abstract][Full Text] [Related]
7. Identification of classical anaphylatoxin as the des-Arg form of the C5a molecule: evidence of a modulator role for the oligosaccharide unit in human des-Arg74-C5a.
Gerard C; Hugli TE
Proc Natl Acad Sci U S A; 1981 Mar; 78(3):1833-7. PubMed ID: 6940191
[TBL] [Abstract][Full Text] [Related]
8. Identification of casoxin C, an ileum-contracting peptide derived from bovine kappa-casein, as an agonist for C3a receptors.
Takahashi M; Moriguchi S; Suganuma H; Shiota A; Tani F; Usui H; Kurahashi K; Sasaki R; Yoshikawa M
Peptides; 1997; 18(3):329-36. PubMed ID: 9145417
[TBL] [Abstract][Full Text] [Related]
9. Conformational analysis of COOH-terminal segments of human C3a. Evidence of ordered conformation in an active 21-residue peptide.
Lu ZX; Fok KF; Erickson BW; Hugli TE
J Biol Chem; 1984 Jun; 259(12):7367-70. PubMed ID: 6610676
[TBL] [Abstract][Full Text] [Related]
10. The primary structure of porcine C3a anaphylatoxin.
Corbin NC; Hugli TE
J Immunol; 1976 Sep; 117(3):990-5. PubMed ID: 956663
[TBL] [Abstract][Full Text] [Related]
11. Suppression of humoral immune responses by synthetic C3a peptides.
Morgan EL; Weigle WO; Erickson BW; Fok KF; Hugli TE
J Immunol; 1983 Nov; 131(5):2258-61. PubMed ID: 6355293
[TBL] [Abstract][Full Text] [Related]
12. Contraction of guinea pig lung by synthetic oligopeptides related to human C3a.
Huey R; Erickson BW; Bloor CM; Hugli TE
Immunopharmacology; 1984 Aug; 8(1):37-45. PubMed ID: 6333413
[TBL] [Abstract][Full Text] [Related]
13. Anaphylatoxin-induced histamine release with human leukocytes: studies of C3a leukocyte binding and histamine release.
Glovsky MM; Hugli TE; Ishizaka T; Lichtenstein LM; Erickson BW
J Clin Invest; 1979 Sep; 64(3):804-11. PubMed ID: 89118
[TBL] [Abstract][Full Text] [Related]
14. Helical conformation at the carboxy-terminal portion of human C3a is required for full activity.
Hoeprich PD; Hugli TE
Biochemistry; 1986 Apr; 25(8):1945-50. PubMed ID: 3486674
[TBL] [Abstract][Full Text] [Related]
15. A recombinant hybrid anaphylatoxin with dual C3a/C5a activity.
Bautsch W; Kretzschmar T; Stühmer T; Kola A; Emde M; Köhl J; Klos A; Bitter-Suermann D
Biochem J; 1992 Nov; 288 ( Pt 1)(Pt 1):261-6. PubMed ID: 1445269
[TBL] [Abstract][Full Text] [Related]
16. Synthetic C3a analogs as specific inhibitors of C3a activity.
Meuer S; Hadding U; Andreatta R; Bitter-Suermann D
Immunopharmacology; 1981 Sep; 3(3):275-80. PubMed ID: 6975766
[TBL] [Abstract][Full Text] [Related]
17. Comparative study on biological activities of various anaphylatoxins (C4a, C3a, C5a). Investigations on their ability to induce platelet secretion.
Meuer S; Hugli TE; Andreatta RH; Hadding U; Bitter-Suermann D
Inflammation; 1981 Dec; 5(4):263-73. PubMed ID: 6976935
[TBL] [Abstract][Full Text] [Related]
18. Mast cells are not required for anaphylatoxin-induced ileal smooth muscle contraction.
Stimler-Gerard NP; Galli SJ
J Immunol; 1987 Mar; 138(6):1908-13. PubMed ID: 2434565
[TBL] [Abstract][Full Text] [Related]
19. Primary structural analysis of the polypeptide portion of human C5a anaphylatoxin. Polypeptide sequence determination and assignment of the oligosaccharide attachment site in C5a.
Fernandez HN; Hugli TE
J Biol Chem; 1978 Oct; 253(19):6955-64. PubMed ID: 690134
[TBL] [Abstract][Full Text] [Related]
20. Complement as a mediator of inflammation. II. Biological properties of anaphylatoxin prepared with purified components of human complement.
Dias Da Silva W; Lepow IH
J Exp Med; 1967 May; 125(5):921-46. PubMed ID: 4960742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
